Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Senzime AB ( (SE:SEZI) ) has provided an announcement.
Senzime AB announced its participation in the Pareto Securities’ 16th Annual Healthcare Conference, where CEO Philip Siberg will present the company’s advancements. This participation underscores Senzime’s commitment to engaging with industry professionals and investors, potentially enhancing its market presence and stakeholder relations.
The most recent analyst rating on (SE:SEZI) stock is a Hold with a SEK6.50 price target. To see the full list of analyst forecasts on Senzime AB stock, see the SE:SEZI Stock Forecast page.
More about Senzime AB
Senzime is a leading medical device company specializing in precision-based monitoring systems that enhance perioperative patient safety. Founded in 1999 and headquartered in Uppsala, Sweden, the company is known for its TetraGraph® system, which is widely used for accurate neuromuscular transmission monitoring during surgery. Senzime is publicly traded on the Nasdaq Stockholm Main Market and cross-traded on the US OTCQX Market.
Average Trading Volume: 501,199
Technical Sentiment Signal: Hold
Current Market Cap: SEK1.02B
See more data about SEZI stock on TipRanks’ Stock Analysis page.